Anaveon, a clinical-stage immuno-oncology company, has announced that the FDA has accepted its Investigational New Drug (IND) application. This milestone allows them to move forward with a Phase I/II study to assess the safety and efficacy of ANV600. The study will include evaluating ANV600 as a standalone treatment and in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, across multiple cancer types.

ANV600 functions by utilizing a non-blocking anti-PD-1 antibody to deliver a targeted IL-2 agonist to tumor-specific T cells. This process aims to stimulate their proliferation and enhance their ability to eliminate tumors. ANV600 is designed to be used alongside approved PD-1 checkpoint inhibitors, allowing for optimal dosing to maximize therapeutic benefits.

Anaveon, emphasized the significance of gaining approval for their first human clinical study of ANV600, citing its promising preclinical efficacy and safety profile. The company is excited about the potential of offering this treatment option to patients.

In March 2024, Anaveon entered into a clinical trial collaboration and supply agreement with MSD to assess ANV600 in combination with KEYTRUDA. Under this agreement, MSD will provide the supply of KEYTRUDA. Anaveon retains all global rights to ANV600.

(KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.)

 

Source: globenewswire.com

Report Abuse